您好,欢迎来到易推广 请登录 免费注册

MedChemExpress 主营产品:Medchemexpress,抑制剂专家,生物试剂公司

易推广认证请放心拨打

021-58955995

当前位置: 易推广 > 生物试剂/抗体/细胞 > 生化试剂 > 其他 > MedChemExpress > 产品展示 > MCE信号通路 > 细胞周期/DNA 损伤 > Lexibulin

提示:信息由商家自行发布,信息的真伪性请消费者自己判断,信息内容的准确性由相关商家负责,易推广对此不承担任何责任。

Lexibulin

价格:¥电议

品牌名称:$brandModel.Title(进口品牌)型号: 原产地:美洲 发布时间:2021/7/29更新时间:2024/1/2

产品摘要:Lexibulin (CYT-997) 是微管蛋白聚集强效抑制剂,对多种癌细胞的 IC50 值为 10-100n M,体外体内具有高效的细胞毒性和血管增生阻断作用。Lexibulin 可诱导细胞凋亡 (apoptosis),并诱导 GC 细胞中的线粒体 ROS 生成。

产品完善度: 访问次数:1599

企业档案

会员类型:会员

已获得易推广信誉   等级评定
171成长值

(0 -40)基础信誉积累,可浏览访问

(41-90)良好信誉积累,可接洽商谈

(91+  )优质信誉积累,可持续信赖

易推广会员:8

工商认证 【已认证】

最后认证时间:

注册号: 【已认证】

法人代表: 【已认证】

企业类型:生产商 【已认证】

注册资金:人民币万 【已认证】

产品数:91228

参观次数:11415217

手机网站:http://m.yituig.com/c131527/

旗舰版地址:http://medchemexpress.app17.com

联系我们

MedChemExpress

电话:021-58955995

联系人:客服部 (请说明是在易推广看到的!谢谢)

手机:13611715263

邮编:201203

邮箱:sales@medchemexpress.cn

地址:上海上海

详细内容

联系方式:
电话:021-58955995 手机:13611715263 联系人:客服部   Q Q:4008203792

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。

Lexibulin

CAS No. : 917111-44-5

MCE 站:Lexibulin

产品活性:Lexibulin (CYT-997) 是微管蛋白聚集强效抑制剂,对多种癌细胞的 IC50 值为 10-100n M,体外体内具有高效的细胞毒性和血管增生阻断作用。Lexibulin 可诱导细胞凋亡 (apoptosis),并诱导 GC 细胞中的线粒体 ROS 生成。

研究领域:Cell Cycle/DNA Damage  |  Cytoskeleton  |  NF-κB  |  Metabolic Enzyme/Protease  |  Immunology/Inflammation  |  Apoptosis

作用靶点:Microtubule/Tubulin  |  Reactive Oxygen Species  |  Apoptosis

In Vitro: Lexibulin (CYT-997) prevents the in vitro polymerization of tubulin with an IC50 of ~3 μmol/L (compared with the half-maximal inhibitory concentration of 2 μmol/L for colchicine under identical conditions) as determined using the conventional turbidimetric assay for tubulin polymerization. Lexibulin is also capable of reversibly disrupting the microtubule network in cells, visualized using fluorescence microscopy. Thus, treatment of A549 cells with Lexibulin (1 μM) lead to the rapid reorganization of microtubules, including the destruction of the existing microtubule network and accumulation of tubulin in plaques within the cytoplasm of some cells. After 24 hours, major alterations in cell morphology are evident, including loss of adhesion and cell rounding. The effect of 1 hour of treatment with Lexibulin is reversible and cells rapidly recovered their normal microtubule architecture. Taken together, the data indicates that Lexibulin belongs to the class of anticancer agents that disrupt, rather than stabilize, tubulin-containing structures. Although vehicle-treated cells show 15% and 19% in G2-M phase at 15 and 24 hours (respectively), cells treated with Lexibulin (1 μM) had 38% and 43% of cells in G2-M at the same time points. Furthermore, at 24 hours post-Lexibulin treatment, only 66% of total cells are in the G1, S, and G2-M phases, which suggests that cells blocked at the G2-M boundary do not exit back to G1, as in the normal cell cycle, but most likely are driven towards apoptosis and cell death. Consistent with the disruption of cellular tubulin, Lexibulin potently inhibits proliferation, induces cell cycle arrest and most importantly apoptosis of both human myeloma cell lines (HMCLs) and primary MM cells.

In Vivo: iIn a xenograft model using the human prostate cancer cell line PC3, oral dosing of Lexibulin (CYT-997) is initiated 13 days after cell implantation by which time palpable tumors were evident. A dose-dependent inhibition of tumor growth was apparent with Lexibulin (CYT-997), which at the highest dose was equivalent to parenterally administered paclitaxel. A single dose of Lexibulin (CYT-997) (7.5 mg/kg i.p.) clearly decreased blood flow in liver metastases, and a significant reduction in blood flow was present 6 hours postdose. Lexibulin (CYT-997) treatment (15 mg/kg/day) significantly prolongs the survival in a murine model of aggressive systemic myelomatosis.

相关产品:Covalent Screening Library Plus  |  Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Apoptosis Compound Library  |  Cell Cycle/DNA Damage Compound Library  |  Immunology/Inflammation Compound Library  |  Metabolism/Protease Compound Library  |  NF-κB Signaling Compound Library  |  Stem Cell Signaling Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Covalent Screening Library  |  Antioxidants Compound Library  |  Oxygen Sensing Compound Library  |  Ferroptosis Compound Library  |  Pyroptosis Compound Library  |  Cytoskeleton Compound Library  |  Orally Active Compound Library  |  Anti-Blood Cancer Compound Library  |  MG-132  |  LY294002  |  Doxorubicin hydrochloride  |  Bafilomycin A1  |  Paclitaxel  |  Y-27632 dihydrochloride  |  Acetylcysteine  |  Angiotensin II human  |  SP600125  |  5-Fluorouracil  |  Staurosporine  |  Bortezomib  |  H2DCFDA  |  Tamoxifen  |  2-Deoxy-D-glucose  |  Gemcitabine  |  Verteporfin  |  Decitabine  |  Actinomycin D  |  Temozolomide  |  BAY 11-7082  |  Etoposide  |  Mitomycin C  |  CCCP  |  DAPT  |  Rote  |  Etomoxir  |  Stattic  |  Docetaxel

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物,我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物;
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域;
•   设有专业的实验中心和严格的质控、验证体系;
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;
•   产品的生物活性多经各国客户实验验证;
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果;
•   专业团队跟踪*新的制药及生命科学研究进展,为您提供全球*新的活性化合物;
•   与世界各大制药公司及知名科研机构建立了长期的合作。

1000+ Inhibitors&Agonists 作用于20多条经典信号通路
30+ Screening Libraries 疾病机制研究的高效工具
CCK8 Kit | Cell Counting Kit-8
FDA-Approved 药物筛选库
Inhibitor Cocktails 蛋白酶, 磷酸酶 & 去乙酰化酶
Top Publications Citing Use of MCE
MCE Hotline: 4008203792 | 中国现货 - 全球文献引用 - 高纯度高品质 - 全方位技术支持
联系方式:
电话:021-58955995 手机:13611715263 联系人:客服部   Q Q:4008203792

热门标签:CYT-997 

快速导航

在线咨询

提交